MRSN

Mersana Therapeutics (MRSN)

About Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Details

Daily high

$27.97

Daily low

$27.36

Price at open

$27.64

52 Week High

$70.73

52 Week Low

$5.21

Market cap

138.8M

Dividend yield

0.00%

Volume

48,270

Avg. volume

248,088

P/E ratio

-1.97

Mersana Therapeutics News